EUVIMEDEUVIMED entdecken
Crossref

Tirzepatide (Zepbound)

CDA-AMC

Canadian Journal of Health Technologies · 14.10.2026 · 6 (10)

DOI: 10.51731/cjht.2026.1538 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 14.10.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses tirzepatide (Zepbound), 2.5mg/0.6 mL, 5 mg/0.6 mL, 7.5 mg/0.6 mL, 10 mg/0.6 mL, 12.5 mg/0.6 mL, and 15 mg/0.6 mL, solution in a multidose prefilled pen for subcutaneous use. Indication: For once-weekly administration for chronic weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial BMI of: 30 kg/m2 or greater (obesity) or 27 kg/m2 to less than 30 kg/m2 (overweight) in the presence of at least 1 weight-related comorbid condition (e.g., hypertension, dyslipidemia, prediabetes, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).

Zitieren

APA

CDA-AMC (2026). Tirzepatide (Zepbound). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1538

Vancouver

CDA-AMC. Tirzepatide (Zepbound). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1538

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Tirzepatide (Zepbound)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {10},
  doi = {10.51731/cjht.2026.1538}
}
Kostenlos starten →